INTRODUCTION {#sec1-1}
============

In pulmonary artery smooth muscle cells (PASMCs), cytosolic Ca^2+^ concentration (\[Ca^2+^\]~cyt~) is mainly regulated by a balance of Ca^2+^ release from intracellular stores and Ca^2+^ influx through plasmalemmal Ca^2+^-permeable channels, as well as Ca^2+^ sequestration into intracellular stores by the Ca^2+^-Mg^2+^ ATPase on the sarcoplasmic/endoplasmic reticulum membrane (SERCA) and Ca^2+^ extrusion via the Ca^2+^-Mg^2+^ ATPase and Na^+^/Ca^2+^ exchanger on the plasma membrane.\[[@ref1][@ref2]\] PASMCs functionally express various Ca^2+^-permeable channels including (a) voltage-dependent Ca^2+^ channels (VDCCs) that are activated by membrane depolarization,\[[@ref3]\] and (*b*) receptor-operated Ca^2+^ (ROC) channels that are stimulated and activated by vasoconstrictors, such as endothelin-1,\[[@ref4]\] serotonin,\[[@ref5]\] phenylephrine,\[[@ref6]\] and histamine,\[[@ref7]\] and by growth factors, including epidermal growth factor\[[@ref8]\] and platelet-derived growth factor.\[[@ref9]\] The activation of ROC channels by interaction between ligands and membrane receptors results in receptor-operated Ca^2+^ entry (ROCE) that greatly contributes to increases in \[Ca^2+^\]~cyt~ in PASMCs exposed to vasoconstrictors and growth factors.\[[@ref1][@ref10][@ref11]\] PASMCs also possess (*c*) store-operated Ca^2+^ (SOC) channels that are opened by the depletion of Ca^2+^ from the sarcoplasmic reticulum (SR), which leads to capacitative Ca^2+^ entry, or store-operated Ca^2+^ entry (SOCE). SOCE is an important mechanism involved in maintaining a sustained elevation of \[Ca^2+^\]~cyt~ and refilling Ca^2+^ into the depleted SR.\[[@ref1][@ref10]--[@ref12]\] We showed previously that increased Ca^2+^ influx through SOC or SOCE contributes to stimulating PASMC proliferation; inhibition of SOCE significantly attenuated growth factor-mediated PASMC proliferation. These results suggest that SOCE plays a significant role in regulating proliferation in vascular smooth muscle cells.\[[@ref9][@ref13][@ref14]\]

It has been well demonstrated that the activity of Ca^2+^-activated Cl^-^ (Cl~Ca~) channels play an important role in regulating contraction, migration, and apoptosis in many cell types.\[[@ref15][@ref16]\] In vascular smooth muscle cells, Cl~Ca~ channels are activated by a rise in \[Ca^2+^\]~cyt~ following agonist-induced Ca^2+^ release from the SR through inositol-1,4,5-trisphosphate receptors (IP~3~Rs). In addition, the activation of Cl~Ca~ channels is evoked by spontaneous Ca^2+^ release through ryanodine receptors in the SR and is responsible for eliciting spontaneous transient inward currents in several types of vascular smooth muscle cells. The intracellular Cl^-^ concentration in vascular smooth muscle cells (including PASMCs) is estimated to be 30 to 60 mM,\[[@ref15]--[@ref17]\] so the reversal potential for Cl^-^ is supposed to be much less negative (ranging from -20 to -30 mV) than that for K^+^ (approximately -80 mV). Therefore, an increase in Cl^-^ conductance in PASMCs under these conditions would generate inward currents (due to Cl^-^ efflux) and cause membrane depolarization which subsequently induces Ca^2+^ influx by opening VDCCs and ultimately results in vasoconstriction. The molecular composition of Cl~Ca~ channels in vascular smooth muscle cells (including PASMCs), however, is not fully identified. Recently, a transmembrane protein encoded by TMEM16A gene has been demonstrated to form Cl~Ca~ channels in vascular smooth muscle cells.\[[@ref18]--[@ref20]\]

In this study, we examined whether Cl~Ca~ channel activity was involved in the regulation of \[Ca^2+^\]~cyt~ via ROCE and SOCE in human PASMCs using digital imaging fluorescence microscopy. We also examined the functional expression of Cl~Ca~ channels (TMEM16A) in human PASMCs using electrophysiological and immunocytochemical approaches.

MATERIALS AND METHODS {#sec1-2}
=====================

Cell culture {#sec2-1}
------------

Human PASMCs (passage 5 to 10) from normal subjects were purchased from Lonza (Walkersville, MD) Cells were cultured in Medium 199 (Invitrogen-GIBCO, Grand Island, NY) supplemented with 10% fetal bovine serum (Invitrogen-GIBCO), 100 U/ml penicillin plus 100 μg/ml streptomycin (Invitrogen-GIBCO), 50 μg/ml D-valine (Sigma-Aldrich, St. Louis, MO), and 20 μg/ml endothelial cell growth supplement (BD Biosciences, Franklin Lakes, NJ) at 37°C. All cells were incubated in a humidified 5% CO~2~ atmosphere at 37°C. After reaching confluence, the cells were sub-cultured by trypsinization with 0.05% trypsin-EDTA (Invitrogen-GIBCO), plated onto 25-mm cover slips (Fisher Scientific, Pittsburgh, PA). and incubated at 37°C for 1-3 days before electrophysiological and fluorescence microscopy experiments.

\[Ca~2+~\]~cyt~ measurement {#sec2-2}
---------------------------

Human PASMCs cultured on 25-mm cover slips were placed in a recording chamber on the stage of an invert fluorescent microscope (Eclipse Ti-E; Nikon, Tokyo, Japan) equipped with an objective lens (S Plan Fluor 20×/0.45 ELWD; Nikon) and an EM-CCD camera (Evolve; Photometrics, Tucson, AZ). \[Ca^2+^\]~cyt~ was monitored using a membrane-permeable Ca^2+^-sensitive fluorescent indicator, fura-2 acetoxymethyl ester (fura-2/AM; Invitrogen-Molecular Probes, Eugene, OR) and imaged with NIS Elements 3.2 software (Nikon). Cells were loaded by incubation in HEPES-buffered solution containing 4 μM fura-2/AM for 60 min. at room temperature (25°C). The loaded cells were then washed with HEPES-buffered solution for 10 min. to remove excess extracellular indicator and allow sufficient time for intracellular esterase to cleave acetoxymethyl ester from fura-2. Cells were then excited at 340-nm and 380-nm wavelengths (D340×v2 and D380×v2 filters, respectively; Chroma Technology, Bellows Falls, VT) by a xenon arc lamp (Lambda LS; Sutter Instrument, Novato, CA) and an optical filter changer (Lambda 10-B; Sutter Instrument). Emission of Fura-2 was collected through a dichroic mirror (400DCLP; Chroma Technology) and a wide band emission filter (D510/80m; Chroma Technology). \[Ca^2+^\]~cyt~ within a region of interest (5×5 μm) that was placed at the peripheral region of each cell was measured as the ratio of fluorescence intensities (F~340~/F~380~) every 2 sec. The HEPES-buffered solution had an ionic composition of 137 mM NaCl, 5.9 mM KCl, 2.2 mM CaCl~2~, 1.2 mM MgCl~2~, 14 mM glucose, and 10 mM HEPES. The pH was adjusted to 7.4 with 10 N NaOH. The external Ca^2+^-free solution was prepared by removing extracellular CaCl~2~ and adding 1 mM EGTA (to chelate the residual Ca^2+^ in the bath solution). The recording chamber was continuously perfused with HEPES-buffered solution at a flow rate of 2 ml/min. using a mini-pump (Model 3385; Control, Friendswood, TX). \[Ca^2+^\]~cyt~ measurements were carried out at 32°C using an automatic temperature controller (TC-344B, Warner Instruments, Holliston, MA).

Electrophysiological recording {#sec2-3}
------------------------------

The whole-cell Cl~Ca~ current in a single PASMC was recorded using the patch-clamp technique with an Axopatch-1D amplifier (Molecular Devices-Axon, Foster City, CA), an analog-digital converter (Digidata 1200; Molecular Devices-Axon), and pCLAMP 8 software (Molecular Devices-Axon). The extracellular (bath) solution had an ionic composition of 137 mM NaCl, 10 mM tetraethylammonium (TEA) chloride, 5 mM 4-aminopyridine (4-AP), 2.2 mM CaCl~2~, 1.2 mM MgCl~2~, 14 mM glucose, and 10 mM HEPES. The pH was adjusted to 7.4 with 10 N NaOH. The low Cl^-^ concentration solution was prepared by substituting 117 mM NaCl of the extracellular solution with the equal molar of sodium gluconate. The pipette (intracellular) solution contained 120 mM CsCl, 20 mM TEA chloride, 4.3 mM CaCl~2~, 2.8 mM MgCl~2~, 2 mM Na~2~ATP, 10 mM HEPES, and 5 mM EGTA. The pCa was fixed to 6.0, which was estimated by the Maxchelator program (<http://www.stanford.edu/~cpatton/maxc.html>). The pH was adjusted to 7.2 with 1 N CsOH. The recording chamber was continuously superfused with extracellular solution at a flow rate of 2 ml/min. using a perfusion system (VC-6; Warner Instrument, Hamden, CT). Electrophysiological recordings were carried out at room temperature (25°C).

Immunocytochemical staining {#sec2-4}
---------------------------

Cultured cells on 35-mm culture dishes with 14-mm glass bottom (MatTek, Ashland, MA) were fixed with 4% paraformaldehyde in Dulbecco\'s phosphate buffered saline (DPBS; Invitrogen-GIBCO) for 10 min. at room temperature (25°C). Excessive paraformaldehyde was removed thoroughly with DPBS. The cells were then treated with DPBS containing 0.2% Triton X-100, 1% normal goat serum (Dako Denmark, Glostrup, Denmark), and TMEM16A antibody (pre-diluted, ab53213, Abcam, Cambridge, MA; or 1:100 dilution, ab53212, Abcam) for 12 hr. at 4°C. After washing repeatedly in DPBS, the cells were covered with DPBS containing 0.2% Triton X-100, 1% normal goat serum, and Alexa Fluor 488-labeled secondary antibody (1:100 dilution; Invitrogen-Molecular Probes) for 1 hr. at room temperature and then rinsed with DPBS. Then cells were mounted in VECTASHIELD hard-set mounting medium with 4',6-diamidino-2-phenylindole (DAPI, 1.5 μg/ml) (Vector Laboratories, Burlingame, CA) and placed on the stage of an invert fluorescent microscope (Eclipse Ti-E; Nikon) equipped with an objective lens (Plan Apo 60×/1.40 oil immersion; Nikon), a CCD camera (CoolSNAP ES^2^; Photometrics), and NIS Elements 3.2 software (Nikon). Immunocytochemical images were obtained using the specific filter sets for DAPI (Ex340-380/DM400/Em435-485; Chroma Technology) and Alexa Fluor 488 (Ex460500/DM505/Em510-560; Chroma Technology).

Drugs {#sec2-5}
-----

Pharmacological reagents were obtained from Sigma-Aldrich. All hydrophobic compounds were dissolved in dimethyl sulfoxide (DMSO) at the concentration of 10 or 100 mM as a stock solution. It was confirmed that up to 0.1 % of DMSO did not affect these responses.

Statistical analysis {#sec2-6}
--------------------

Pooled data are shown as the mean±SE. The statistical significance between two groups was determined by Student\'s t-test. The statistical significance among groups was determined by Scheffé\'s test after one-way analysis of variance. Significant difference is expressed in the figures as ^\*^P\<0.05 or ^\*\*^P\<0.01.

RESULTS {#sec1-3}
=======

Inhibition of agonist-induced Ca^2+^ influx or ROCE by Cl~Ca~ channel blockers in human PASMCs {#sec2-7}
----------------------------------------------------------------------------------------------

The increase in \[Ca^2+^\]~cyt~ evoked by agonist stimulation was imaged in human PASMCs loaded with 4 μM fura-2/AM and quantitated in arbitrary units (au) by the change in *F*~340~/*F*~380~ ratio. Short-term application (2 min.) of 100 nM angiotensin II induced a transient increase in \[Ca^2+^\]~cyt~ (by 0.49±0.01 au, n=150) (Figs. [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). The angiotensin II-induced \[Ca^2+^\]~cyt~ increase was attenuated by 100 μM niflumic acid, a fenamate compound that is most frequently used as a blocker of Cl~Ca~ channels (from 0.51±0.03 to 0.13±0.02 au, n=29, P\<0.01) (Fig. [1a](#F1){ref-type="fig"} and [d](#F1){ref-type="fig"}). The inhibitory effect of niflumic acid on the angiotensin II-mediated increase in \[Ca^2+^\]~cyt~ was reversible upon washout (0.42±0.04 au, n=29). Pretreatment with 100 μM flufenamic acid, another fenamate compound that blocks Cl~Ca~ channels, markedly reduced the angiotensin II-induced \[Ca^2+^\]~cyt~ increase (from 0.51±0.02 to 0.13±0.03 au, n=33, P\<0.01) (Fig. [1b](#F1){ref-type="fig"} and [e](#F1){ref-type="fig"}). A different type of Cl^-^ channel blocker, 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS)-one of the stilbene derivatives that is structurally unrelated to fenamates--also caused a significant inhibition of the angiotensin II-induced \[Ca^2+^\]~cyt~ increase (from 0.43±0.04 to 0.06±0.01 au, n=18, P\<0.01) (Fig. [1c](#F1){ref-type="fig"} and [f](#F1){ref-type="fig"}). These data indicated that the function of Cl~Ca~ channels is involved in regulating ROCE in human PASMCs; inhibition of Cl~Ca~ channels significantly and reversibly attenuates the agonist-mediated Ca^2+^ entry.

![Attenuation of ROCE by Cl~Ca~ channel blockers in human PASMCs. Angiotensin II (AngII, 100 nM) was used to induce ROCE in human PASMCs. (a-c) Representative traces showing angiotensin II-induced \[Ca^2+^\]~cyt~ increases in human PASMCs before, during, and after application of 100 μM niflumic acid (NFA; a), flufenamic acid (FFA; b), and DIDS (c). Blockage of ClCa channels reduces angiotensin II-induced \[Ca^2+^\]~cyt~ elevation in human PASMCs. (d-f) Summarized data showing the reversible inhibitory effects of niflumic acid (d), flufenamic acid (e), and DIDS (f) on angiotensin II-induced \[Ca^2+^\]~cyt~ rises in human PASMCs. Statistical significance (versus control) is indicated as ^\*\*^P\<0.01.](PC-1-269-g001){#F1}

![Effects of Ca^2+^ channel blockers on ROCE in human PASMCs. Angiotensin II (AngII, 100 nM) was used to induce ROCE in human PASMCs. (a-c) Representative traces showing angiotensin II-induced \[Ca^2+^\]~cyt~ rises in human PASMCs before, during, and after application of 50 μM SKF-96365 (SKF, an inhibitor of nonselective cation channels; a), 100 μM 2-APB (which blocks IP3Rs and also non-selective cation channels; b), and 10 μM diltiazem (a VDCC blocker; c). (d-f) Summarized data showing effects of SKF-96365 (d), 2-APB (e), and diltiazem (f) on angiotensin II-induced \[Ca^2+^\]~cyt~ increase in human PASMCs. Statistical significance (versus control) is indicated as ^\*\*^P\<0.01.](PC-1-269-g002){#F2}

Effects of Ca^2+^ channel blockers on ROCE in human PASMCs {#sec2-8}
----------------------------------------------------------

To elucidate the Ca^2+^ signal pathway for angiotensin II-induced ROCE, effects of the inhibitors for several different types of Ca^2+^ channels were examined in human PASMCs. The angiotensin II-mediated increase in \[Ca^2+^\]~cyt~ was reduced by treatment with 50 μM SKF-96365, an inhibitor of non-selective cation channels (from 0.59±0.05 to 0.28±0.04 au, n=13, P\<0.01) (Fig. [2a](#F2){ref-type="fig"} and [d](#F2){ref-type="fig"}). The application of 100 μM 2-aminoethoxydiphenylborate (2-APB), which blocks IP~3~ Rs and also non-selective cation channels, abolished the angiotensin II-induced increase in \[Ca^2+^\]~cyt~ (from 0.46±0.03 to 0.08±0.01 au, n=22, P\<0.01) (Fig. [2 b](#F2){ref-type="fig"} and [e](#F2){ref-type="fig"}). Blockage of VDCC with 10 μM diltiazem, however, had a trend to inhibit the angiotensin II-induced \[Ca^2+^\]~cyt~ increase (from 0.45±0.02 to 0.36±0.03 au, n=35, P\>0.05 by Scheffé\'s test, but P\<0.01 by Student\'s *t*-test) (Fig. [2 c](#F2){ref-type="fig"} and [f](#F2){ref-type="fig"}). These pharmacological data indicate that the angiotensin II-induced \[Ca^2+^\]~cyt~ increase was mainly caused by Ca^2+^ release from the SR through IP~3~R followed by Ca^2+^ influx via non-selective cation channels in human PASMCs. Ca^2+^ influx through the diltiazem-sensitive L-type VDCCs slightly contributes to the angiotensin II-induced rise of \[Ca^2+^\]~cyt~ in human PASMCs.

Inhibitory effect of Cl~Ca~ channel blockers on SOCE in human PASMCs {#sec2-9}
--------------------------------------------------------------------

In the next set of experiments, we examined the effect of Cl~Ca~ channel blockers on SOCE in human PASMCs ([Fig. 3](#F3){ref-type="fig"}). SOCE was induced by passive depletion of Ca^2+^ from the SR with 10 μM cyclopiazonic acid (CPA), a blocker of SERCA. In the absence of extracellular Ca^2+^, application of CPA induced a transient increase in \[Ca^2+^\]~cyt~ that was due predominantly to Ca^2+^ leakage from the SR to the cytosol. Restoration of extracellular Ca^2+^ after approximately 10 min. treatment with CPA caused another increase in \[Ca^2+^\]~cyt~ that was apparently due to Ca^2+^ influx through store-operated cation (or Ca^2+^) channels or SOCE.

![Attenuation of SOCE by Cl~Ca~ channel blocker in human PASMCs. SOCE was induced by passive depletion of Ca^2+^ from the SR with 10 μM CPA in human PASMCs. (a) Typical trace of CPA-induced Ca^2+^ release and SOCE in the absence (vehicle, 0.1% DMSO) and presence of 100 μM niflumic acid (NFA) in a human PASMC. Blockage of ClCa channels caused a reduction of SOCE in human PASMCs. (b-d) Summarized data showing effects of niflumic acid on the resting \[Ca^2+^\]~cyt~ (b), the rise speed of SOCE (c), the transient and plateau amplitudes of CPA-induced SOCE (d) in human PASMCs. Statistical significance versus vehicle control is indicated as \*P\<0.05 or \*\<0.01.](PC-1-269-g003){#F3}

As shown in [Figure 3](#F3){ref-type="fig"}, there were no significant differences in the resting \[Ca^2+^\]~cyt~ (0.59±0.02 versus 0.62±0.02 au, n=55, P=0.25) and the amplitude of the increase in \[Ca^2+^\]~cyt~ due to CPA-induced Ca^2+^ leakage from the SR to the cytosol when cells were treated with 100 μM niflumic acid or vehicle (0.1% DMSO) (Fig. [3 a](#F3){ref-type="fig"} and [b](#F3){ref-type="fig"}). The transient and plateau phases of CPA-induced increases in \[Ca^2+^\]~cyt~ due to SOCE, as well as the amplitude and "rise-speed" of SOCE were all significantly decreased by 100 μM niflumic acid. The rise-speed of SOCE in the presence of niflumic acid (0.18±0.01 ratio/s, n=55) was significantly slower than that in the absence (0.36±0.04 ratio/s, P\<0.01 ([Fig. 3c](#F3){ref-type="fig"}). In addition, application of niflumic acid significantly reduced the amplitude of the transient (from 0.42±0.02 to 0.31±0.02 au, n=55; P\<0.01) and plateau (from 0.15±0.01 to 0.10±0.01 au, n=55; P=0.02) phases of SOCE (Fig. [3a](#F3){ref-type="fig"} and [d](#F3){ref-type="fig"}). Treatment of the cells with 100 μM flufenamic acid also significantly decreased the amplitude of the transient and plateau phases of CPA-induced SOCE in human PASMCs (n=34). These data clearly suggest that the activity of Cl~Ca~ channels is involved in regulating SOCE in human PASMCs.

Effects of Ca^2+^ channel blockers on SOCE in human PASMCs {#sec2-10}
----------------------------------------------------------

To functionally define the Ca^2+^ channels responsible for CPA-mediated SOCE, we examined the effects of different Ca^2+^ channel blockers on SOCE in human PASMCs. The transient component of CPA-induced SOCE was significantly reduced by 50 μM SKF-96365 (0.21±0.01 au, n=51, versus vehicle control, 0.37±0.01 au, n=58; P\<0.01) (Fig. [4 a](#F4){ref-type="fig"}, [b](#F4){ref-type="fig"} and [e](#F4){ref-type="fig"}) and 100 μM 2-APB (0.10±0.01 au, n=46, P\<0.01) (Fig. [4 c](#F4){ref-type="fig"} and [e](#F4){ref-type="fig"}). Application of 10 μM diltiazem slightly (but significantly) affected the transient component of SOCE (from 0.37±0.01 to 0.32±0.01 au, n=42, P\<0.01), but had no effect on the plateau phase of SOCE (from 0.16±0.01 au, n=58, to 0.14±0.01 au, n=42, P=0.22) (Fig. [4 a](#F4){ref-type="fig"}, [d](#F4){ref-type="fig"} and [e](#F4){ref-type="fig"}). Similar to their effects on the transient phase of SOCE, 50 μM SKF-96365 (from 0.16±0.01, n=58, to 0.06±0.01 au, n=51; P\<0.01) (Fig. [4a](#F4){ref-type="fig"}, [b](#F4){ref-type="fig"} and [e](#F4){ref-type="fig"}) or 100 μ 2-APB (to 0.05±0.01 au, n=46, P\<0.01) (Fig. [4c](#F4){ref-type="fig"} and [e](#F4){ref-type="fig"}) also significantly reduced the plateau phase of CPA-induced SOCE. These pharmacological data indicate that the Ca^2+^ signaling pathway for CPA-induced SOCE was mainly dependent on Ca^2+^ influx through non-selective cation channels in human PASMCs. The activity of VDCCs might be, in part, involved in the Ca^2+^ influx pathway in human PASMCs.

![Effects of Ca^2+^ channel blockers on SOCE in human PASMCs. SOCE was induced by passive depletion of Ca^2+^ from the SR with 10 μM CPA in human PASMCs. (a-d) Typical traces showing CPA-induced Ca^2+^ release and SOCE in the absence (vehicle, 0.1% DMSO; a) and presence of 50 μM SKF-96365 (SKF, a blocker for non-selective cation channels; b), 100 μM 2-APB (a blocker of IP3Rs and non-selective cation channels; c), and 10 μM diltiazem (an inhibitor of VDCCs; d) in human PASMCs. (e) Summarized data showing effects of Ca^2+^ channel blockers on the transient and plateau amplitudes of CPA-induced SOCE in human PASMCs. The number of cells examined is given in parentheses. Statistical significance versus vehicle control is indicated as ^\*\*^P\<0.01.](PC-1-269-g004){#F4}

Whole-cell Cl~Ca~ currents in human PASMCs {#sec2-11}
------------------------------------------

Electrophysiological and pharmacological properties of Cl~Ca~ currents in human PASMCs were analyzed by whole-cell patch-clamp configuration using a pipette (intracellular) solution containing 120 mM Cs^+^, 20 mM TEA (pCa=6.0) and a bath (extracellular) solution containing 10 mM TEA and 5 mM 4-AP. The mean cell-capacitance was 9.0±1.2 pF (n=14). Depolarizing pulses (500 ms) were applied from a holding potential of -60 mV to a series of test potentials ranging from -80 to +100 mV by 20-mV increments every 15 sec. Outward currents were elicited by depolarization from the holding potential to the positive potentials above 0 mV, and the averaged current density at +100 mV was 86±7 pA/pF (n=14) (Fig. [5 a](#F5){ref-type="fig"} and [b](#F5){ref-type="fig"}). The reversal potential of the whole-cell currents was -3.4±1.3 mV (n=14) ([Fig. 5b](#F5){ref-type="fig"}), which is close to the theoretical (or calculated) equilibrium potential of Cl^-^ (+0.1 mV). In addition, the reversal potential was shifted positively (to the right) by approximately 30 mV (positive shift by 36 mV in theory) by changing the extracellular Cl^-^ concentration from 153.8 to 36.8 mM (data not shown). Importantly, we were able to detect inward "tail" currents when cells were repolarized to the holding potential ([Fig. 5a](#F5){ref-type="fig"}), which is an important characteristic of Cl~Ca~ currents. Furthermore, we analyzed the tail currents and the current-voltage relationship using the pulse protocol as follows: depolarizing pre-pulses were applied from a holding potential of -60 to +100 mV for 100 ms and subsequently test pulses were applied between -40 to +40 mV by 10-mV increments for 500 ms every 15 sec. ([Fig. 5c](#F5){ref-type="fig"}). The current-voltage relationship revealed that the reversal potential of the tail currents (1.9±0.9 mV, n=4; [Fig. 5d](#F5){ref-type="fig"}) was also very close to the theoretical (or calculated) equilibrium potential of Cl^-^.

![Whole-cell ClCa currents in human PASMCs. Cl~Ca~ currents were measured using a pipette solution containing 120 mM Cs^+^, 20 mM TEA and pCa 6.0, and a bath solution containing 10 mM TEA and 5 mM 4-AP in human PASMCs. (a) Representative outward currents (black arrowhead), elicited by depolarization from a holding potential of -60 mV to a series of test potentials (-80 to +100 mV) for 500 ms every 15 sec. and inward tail currents (gray arrowhead), induced by repolarization to -60 mV in a human PASMC. (b) I-V relationship at peak amplitude during depolarization (black arrowhead in "a"). The current reverses at about 0 mV, the theoretical equilibrium potential of Cl-. (c) Representative tail currents (gray arrowhead) at a series of test potentials (-40 to +40 mV) for 500 ms after depolarization from a holding potential of -60 to +100 mV for 100 ms every 15 sec. in a human PASMC. (d) I-V relationship of tail currents (gray arrowhead in "c"). The reversal potential is close to 0 mV.](PC-1-269-g005){#F5}

Application of 100 μM niflumic acid significantly attenuated both the outward Cl~Ca~ current and the inward tail current in human PASMCs ([Fig. 6](#F6){ref-type="fig"}). Niflumic acid decreased the outward currents elicited by depolarization from a holding potential of -60 to +60 mV (for 500 ms every 15 s) (from 37.4±5.3 to 16.5±1.2 pA/pF, n=3; P=0.046). The inward tail currents were also inhibited by the pretreatment with niflumic acid (-5.6±1.3 pA/pF, n=3, versus control of -22.2±4.7 pA/pF, P=0.040). These electrophysiological data indicate that Cl~Ca~ channels sensitive to niflumic acid are functionally expressed in human PASMCs.

![Inhibition of Cl~Ca~ currents by niflumic acid in human PASMCs. Effect of niflumic acid on whole-cell Cl~Ca~ currents was examined in human PASMCs. (a) Representative outward currents (black arrowhead), elicited by depolarization from a holding potential of -60 to +60 mV, and inward tail currents (gray arrowhead), induced by repolarization to -60 mV in the absence (black line) and presence (gray line) of 100 μM niflumic acid (NFA) in a human PASMC. (b) Summarized data showing the effect of niflumic acid on outward (black arrowhead in "a") and tail (gray arrowhead in "a") currents in human PASMCs. The number of cells examined is given in parentheses. Statistical significance versus control is indicated as \*P\<0.05.](PC-1-269-g006){#F6}

Expression of TMEM16A in human PASMCs {#sec2-12}
-------------------------------------

The molecular basis of Cl~Ca~ channels in human PASMCs was identified by an immunocytochemical approach using two specific primary antibodies of TMEM16A (ab53213 and ab53212 from Abcam), a potential protein candidate for Cl~Ca~ channels. Immunocytochemical experiments ([Fig. 7](#F7){ref-type="fig"}) revealed that specific fluorescent signals of TMEM16A protein were localized in the cell membrane. Qualitatively, the same images were obtained from 3 separate sets of experiments. This result indicates that the activity of Cl~Ca~ channels in human PASMCs is potentially due to channels formed by TMEM16A.

![Expression of TMEM16A in human PASMCs. Immunocytochemical analysis of TMEM16A, a potential candidate for the Cl~Ca~ channel subunit, was performed in human PASMCs using two specific primary antibodies (ab53213 and ab53212 from Abcam). Alexa Fluor 488 and DAPI were used as a secondary antibody and a nuclear marker, respectively. Specific signals of TMEM16A protein were detected on the plasma membranes of human PASMCs. Similar immunocytochemical images were obtained from 3 sets of independent experiments.](PC-1-269-g007){#F7}

DISCUSSION {#sec1-4}
==========

In vascular smooth muscle cells, Cl~Ca~ channels are present for diverse physiological and pathological functions. In this study, we showed that the blockage of Cl~Ca~ channels using pharmacological tools markedly attenuated both ROCE and SOCE in human PASMCs. Our electrophysiological and immunocytochemical data also indicated that the activity of Cl~Ca~ channels functionally expressed in human PASMCs was due potentially to channels formed by TMEM16A proteins.

Intracellular free Ca^2+^ plays an important role in the regulation of contraction, proliferation, and migration of PASMCs. An increase in \[Ca^2+^\]~cyt~ in PASMCs is a major trigger for pulmonary vasoconstriction and an important stimulus for PASMC proliferation that leads to pulmonary vascular remodeling under pathological conditions. Elevation of \[Ca^2+^\]~cyt~ in PASMCs results from Ca^2+^ release from intracellular stores, such as the SR, and Ca^2+^ influx through plasmalemmal Ca^2+^ channels, such as ROC channels, SOC channels, and VDCCs.\[[@ref1][@ref2]\]

Angiotensin II is a vasoconstrictor that is commonly used for eliciting agonist-induced \[Ca^2+^\]~cyt~ rises in PASMCs and other vascular smooth muscle cells.\[[@ref21][@ref22]\] In this study, we used angiotensin II to induce ROCE because, at the concentration of 100 nM, it caused an increase in \[Ca^2+^\]~cyt~ in a large number of human PASMCs (\>70%). The angiotensin II-mediated increase in \[Ca^2+^\]~cyt~ via ROCE was markedly reduced by two different types of Cl~Ca~ channel inhibitors, fenamates (niflumic acid and flufenamic acid) and one of the stilbene derivatives (DIDS). Both niflumic acid and flufenamic acid are well known fenamates that are most frequently used as Cl~Ca~ channel blockers in electrophysiological and pharmacological studies. However, these compounds have been reported to also act on other types of ion channels such as non-selective cation channels,\[[@ref23]\] large-conductance Ca^2+^-activated K^+^ channels,\[[@ref24]\] and transient receptor potential canonical subfamily (TRPC) channels.\[[@ref25]\] Therefore, to confirm whether or not the inhibitory effects of niflumic acid and flufenamic acid on the angiotensin II-evoked increase in \[Ca^2+^\]~cyt~ in human PASMCs were mediated by the blockage of Cl~Ca~ channels, we analyzed the effects of another type of Cl~Ca~ channel blocker, DIDS, a stilbene derivative that is structurally unrelated to fenamates, on the angiotensin II-induced \[Ca^2+^\]~cyt~ increase. Similar to niflumic acid and flufenamic acid, DIDS also significantly suppressed the angiotensin II-induced \[Ca^2+^\]~cyt~ increase, although it might have interfered with the fura-2 fluorescence due to its faint yellow colored solution at a concentration of 100 μM. These results, by using two different types of Cl~Ca~ channel blockers, strongly suggest that the function of Cl~Ca~ channels is involved in regulating ROCE in human PASMCs.

SOCE is essential for maintaining a high level of \[Ca^2+^\]~cyt~ and for refilling intracellular Ca^2+^ stores (i.e., SR) in smooth muscle cells.\[[@ref1][@ref10]--[@ref12]\] High levels of \[Ca^2+^\]~cyt~ and sufficient levels of Ca^2+^ in the SR are required for proliferation of vascular smooth muscle cells.\[[@ref1][@ref10]\] SOCE is enhanced while SOC channels are upregulated during PASMC proliferation to increase Ca^2+^ influx and provide sufficient Ca^2+^ for activation of the intracellular mechanisms responsible for cell proliferation and growth.\[[@ref9][@ref13][@ref14]\] In the present study, we demonstrated that the blockage of Cl~Ca~ channels by niflumic acid and flufenamic acid reduced both the transient and plateau components of SOCE as well as the rise speed of SOCE in human PASMCs. These data indicate that the function of Cl~Ca~ channels is also involved in regulating SOCE in human PASMCs (in addition to the effect on ROCE). Suppression of SOCE by blockage of Cl~Ca~ channels is thought to cause reduced PASMC proliferation, which may be a novel strategy for preventing the abnormal proliferation under pathological conditions. TRPC channels have been demonstrated to be involved in agonist- or growth factor-mediated Ca^2+^ entry in PASMCs,\[[@ref1][@ref10][@ref26]\] while functional coupling of stromal interaction molecule (STIM) proteins (STIM1 and STIM2) with TRPC and/or Orai channels have recently been suggested as a novel candidate for SOC channel subunits in PASMCs.\[[@ref27]--[@ref29]\] TRPC channel genes are thought to encode pore-forming subunits that compose ROC\[[@ref30]--[@ref32]\] and SOC\[[@ref33]--[@ref35]\] channels in many cell types of vascular smooth muscles including PASMCs.\[[@ref9][@ref13][@ref14][@ref36]--[@ref38]\] Ca^2+^ entry via ROC and SOC channels is modulated by second messengers, phosphorylation of signal transduction proteins, and transcription factors.\[[@ref2][@ref10][@ref39]\] The protein expression levels of TRPC, STIM and Orai are changed under pathological conditions such as in pulmonary arterial hypertension.\[[@ref1][@ref10][@ref39]\]

Smooth muscle cells contain a high concentration of Cl^-^ in the intracellular space, which is considerably different from other cell types, such as neurons, cardiomyocytes, and skeletal muscle myocytes.\[[@ref17]\] Therefore, increases in Cl^-^ conductance across the plasma membrane (e.g., as a result of activation of Cl~Ca~ channels when \[Ca^2+^\]~cyt~ is increased) lead to Cl^-^ efflux and inward currents, which consequently causes membrane depolarization, enhanced Ca^2+^ influx through VDCCs, increased \[Ca^2+^\]~cyt~, and vasoconstri-ction.\[[@ref15][@ref16]\] In the present study, electrophysiological data indicated that Cl~Ca~ channels were functionally expressed in human PASMCs and the Cl^-^ currents through Cl~Ca~ channels were sensitive to niflumic acid. The electrophysiological properties (e.g., the time-dependent outward current during membrane depolarization, the inward tail current during repolarization, the outward rectification, and the shift of reversal potential based on the change in extracellular Cl^-^ concentration) and pharmacological properties (e.g., the dependency on intracellular Ca^2+^ concentration and the sensitivity to niflumic acid) of whole-cell Cl~Ca~ currents obtained from human PASMCs were consistent with the same properties reported previously in PASMCs from rabbits\[[@ref40]\] and rats.\[[@ref41][@ref42]\] The \[Ca^2+^\]~cyt~ increase mediated by ROCE and SOCE also activates the Cl~Ca~ channels, resulting in membrane depolarization followed by additional Ca^2+^ influx through VDCCs. Slight decreases in ROCE and SOCE by diltiazem, a VDCC blocker, suggested that VDCCs only partly contributed to the regulation of ROCE and SOCE, although the Ca^2+^ influx pathway was mainly due to non-selective Ca^2+^ channels sensitive to SKF-96365 and 2-APB in human PASMCs.

Cl~Ca~ channels play important roles in diverse functions in vascular smooth muscle cells. In spite of its physiological and pathological significances, the molecular architecture of Cl~Ca~ channels in vascular smooth muscle cells has not been clearly demonstrated. More recently, the TMEM16 family, consisting of 10 genes in mammals, has been found as a novel candidate for Cl~Ca~ channel subunits.\[[@ref18]--[@ref20][@ref43]\] Heterologous expression of TMEM16A has been shown to generate Cl^-^ currents sensitive to intracellular Ca^2+^ and with the degree of outward rectification, ion selectivity, and pharmacological profile\[[@ref18]--[@ref20]\] similar to the activity of native Cl~Ca~ channels observed in many tissues containing interstitial cells of Cajal in gastrointestinal muscles,\[[@ref44]--[@ref46]\] airway epithelial cells,\[[@ref47][@ref48]\] as well as vascular smooth muscle cells.\[[@ref42][@ref49]\] The distribution pattern of TMEM16A in interstitial cells of Cajal in gastrointestinal muscles,\[[@ref44]--[@ref46][@ref50]\] airway epithelial cells,\[[@ref47][@ref48]\] and vascular smooth muscle cells\[[@ref49]\] implies the functional expression of Cl~Ca~ conductance. In this study, TMEM16A protein was localized in the plasma membrane of human PASMCs, indicating that the activity of the Cl~Ca~ channel in human PASMCs was, at least in part, due to channels formed by TMEM16A. It has been reported that the TMEM16A gene also has some splice variants\[[@ref18][@ref42][@ref49][@ref51]\] and TMEM16B, a closely related analogue, also can generate Cl^-^ currents activated by Ca^2+^.\[[@ref19][@ref52]--[@ref54]\] It is unclear whether TMEM16B is another subunit that forms Cl~Ca~ channels in human PASMCs.

Pulmonary arterial hypertension is a fatal and progressive disease characterized pathologically by severe pulmonary vascular remodeling. A central aspect of pulmonary vascular remodeling is adventitial, medial, and intimal hypertrophy caused by excessive proliferation of fibroblasts and myofibroblasts in the adventitia, PASMCs in the media and endothelial cells in the intima. The concentric pulmonary vascular wall remodeling or thickened arterial and arteriole wall, narrows the intra-arterial lumen, increases pulmonary vascular resistance and ultimately causes pulmonary hypertension.\[[@ref2][@ref39]\] Since SOC and ROC channels are upregulated in PASMC isolated from patients with idiopathic pulmonary arterial hypertension (IPAH) and from animals with hypoxia-mediated pulmonary hypertension, Ca^2+^ entry through these upregulated cation channels may play an important pathogenic role in the initiation and progression of pulmonary vascular remodeling under the pathological conditions.\[[@ref1][@ref10][@ref14][@ref26][@ref28][@ref37]\] It remains unclear, however, whether the activity of Cl~Ca~ channels is also involved in the sustained pulmonary vasoconstriction and excessive pulmonary vascular remodeling in patients with IPAH and animals with hypoxia-induced pulmonary hypertension. Based on the observations from this study, the attenuation of SOCE and ROCE by Cl~Ca~ channel blockers (e.g., niflumic acid, flufenamic acid, and DIDS) may serve as a potential therapeutic approach for pulmonary vascular disease. Although it is suggested that Cl^-^ channels are involved in SOCE and proliferation in PASMCs,\[[@ref55][@ref56]\] further experiments are necessary to elucidate the mechanism underlying the regulation of ROCE and SOCE by Cl~Ca~ channels in human PASMCs.
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